Here's a look at some of the top regulatory stories for medical device companies this week: Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together; Medtronic and Covidien prepare 1st Integration Summit; FTC approves Cerner's $1.3B Siemens health IT buy; Alere unveils $3.82B privatization plan; Medtronic, Covidien slide on new U.S. inversion rules
Cerner gets federal approval for its $1.3 billion acquisition of Siemens' health information technology business.
Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter
Beckman Coulter picks up Siemens Healthcare Diagnostics' clinical microbiology business in a closed-doors deal.
Siemens is reportedly investigating a spinout of its Siemens Healthcare division's IT unit, which could be worth more than $1 billion.
Chatter about a possible spinout for Siemens Healthcare (NYSE:SI) ramped up yesterday on a report from "2 people familiar with the plans" who said the German conglomerate is actively investigating a possible sale of its hospital database and IT business.
MALVERN, Pa. -- Siemens Healthcare has announced that it recently submitted to the U.S. Food and Drug Administration (FDA) its premarket approval application (PMA) for the MAMMOMAT Inspiration® with Breast Tomosynthesis option.
Siemens files a premarket approval application to add 3D breast imaging to its Mammomat Inspiration digital mammograms.
Healthcare giant Siemens (NYSE:SI) this week filed its premarket approval application to get the FDA's OK to add a tomosynthesis option to its Mammomat Inspiration mammography system.